Gossamer Bio, Inc.
GOSS
Rank in Stocks
#21612
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Share Price
$10.65
Last synced: 2026-11-09
Market Cap
$65.05M
Change (1 day)
8.96%
Change (1 year)
311.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Gossamer Bio, Inc. (GOSS)
Category
Healthcare
EPS for Gossamer Bio, Inc. (GOSS)
EPS as of June 2026 TTM: $-45.32
According to Gossamer Bio, Inc.'s latest financial reports, its current EPS (TTM) is $-45.32. At the end of 2025 the company had an EPS of $-59.64, a decrease compared to its 2024 EPS of $-19.99.
EPS history for Gossamer Bio, Inc. from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-45.32 | -24.01% |
| 2025 | $-59.64 | 198.35% |
| 2024 | $-19.99 | -78.79% |
| 2023 | $-94.26 | -56.56% |
| 2022 | $-216.97 | -13.26% |
| 2021 | $-250.13 | -11.98% |
| 2020 | $-284.17 | 7.84% |
| 2019 | $-263.51 | -85.42% |
| 2018 | $-1.81K | 2,956.81% |
| 2017 | $-59.13 | 8,112.50% |
| 2016 | $-0.72 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -134.55% |
US
|
|
| $-7.07 | -84.40% |
US
|
|
| $-5.29 | -88.33% |
AU
|
|
| $12.88 | -128.42% |
BE
|
|
| $21.56 | -147.57% |
NL
|
Questions about Gossamer Bio, Inc.'s earnings per share (EPS)
What is Gossamer Bio, Inc.'s earnings per share (EPS)?
Gossamer Bio, Inc.'s earnings per share (EPS) over the last twelve months is $-45.32, as of Jun 2026.
What was Gossamer Bio, Inc.'s earnings per share (EPS) in 2025?
In 2025, Gossamer Bio, Inc.'s earnings per share (EPS) was $-59.64, compared with $-19.99 in 2024.
How has Gossamer Bio, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Gossamer Bio, Inc.'s earnings per share (EPS) was highest in 2024 ($-19.99) and lowest in 2020 ($-284.17).
How does Gossamer Bio, Inc.'s earnings per share (EPS) compare with similar companies?
Gossamer Bio, Inc.'s earnings per share (EPS) ($-45.32) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.